USA News Group News
Commentary
Issued on behalf of Oncolytics Biotech
Inc.
VANCOUVER, BC, June 20, 2024 /PRNewswire/ -- USA News Group News
Commentary – The potential threat of cancer looms for
everyone, but now new studies are revealing an increased number of
cancer cases in younger age groups than before. While
researchers continue to search for a reason why this is happening,
some are pointing towards increased rates of obesity, among other
potential reasons. With the Global Oncology Drugs Market set
to grow by 11.5% CAGR through 2033 to US$564.5 billion, according to Spherical
Insights, the need for more effective therapies is becoming
more apparent. The biotech sector continues to work diligently,
spotlighted by several developments recently announced by
companies, including: Oncolytics Biotech Inc.
(NASDAQ: ONCY) (TSX: ONC), Mustang Bio, Inc. (NASDAQ: MBIO),
Legend Biotech Corporation (NASDAQ: LEGN), Johnson &
Johnson (NYSE: JNJ), and Nurix Therapeutics, Inc.
(NASDAQ: NRIX).
The article continued: Last year, the FDA granted a total
of 50 approvals for various oncology drugs. This year, the
National Cancer Institute projects there will be an
estimated 2,001,140 new cases of cancer diagnosed in the
USA in 2024, with an expected
611,720 people projected to die from the disease.
Oncolytics Biotech® Doses First Patient in Study of
Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic
Cancer
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a
leading clinical-stage company specializing in immunotherapy for
oncology, today announced the dosing of the first patient
in the new GOBLET study cohort evaluating pelareorep and modified
FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®)
in newly diagnosed metastatic pancreatic ductal adenocarcinoma
(PDAC) patients. The co-primary endpoints of the cohort are
objective response rate (ORR) and safety. It's supported by the
US$5M Pancreatic Cancer Action
Network (PanCAN) Therapeutic Accelerator Award, an innovative
program established to accelerate the development of new treatments
for pancreatic cancer patients. It will be conducted in
collaboration with AIO-Studien-gGmbH (AIO), a clinical trial group
within the German Cancer Society, as part of GOBLET, a Phase
1/2 multiple indication study evaluating pelareorep-based
combinations in gastrointestinal cancers.
"Initiation of dosing in the mFOLFIRINOX cohort of the GOBLET
study is an important milestone for Oncolytics, and we're
excited to begin evaluating another pelareorep combination therapy
that could result in a second pancreatic cancer registration
program for the company," said Thomas
Heineman, M.D., Ph.D., Chief Medical Officer at
Oncolytics. "The combination of pelareorep, atezolizumab,
gemcitabine, and nab-paclitaxel in pancreatic cancer patients more
than doubled tumor response rates compared to earlier trials of
chemotherapy alone. That combination received Fast Track
Designation from the FDA and is expected to be evaluated in
an adaptive registration-enabling trial through the Global
Coalition for Adaptive Research (GCAR). If the combination of
pelareorep and mFOLFIRINOX also demonstrates a promising efficacy
signal, we could have two pancreatic cancer treatment regimens on
the path to registration. I want to highlight PanCAN's
important support for this program with gratitude. The US$5M Therapeutic Accelerator Award has made it
possible for us to broaden our evaluation of potential therapies
that have the potential to improve outcomes for pancreatic cancer
patients."
Anna Berkenblit, MD, MMSc, Chief
Scientific and Medical Officer at PanCAN said, "Working
toward our vision to create a world in which all patients with
pancreatic cancer will thrive, PanCAN launched the
Therapeutic Accelerator Award to speed the drug development process
and bring new options to patients faster. Dosing the first patient
in this new cohort of the GOBLET study is an important step toward
further evaluation of this investigational immunotherapeutic
approach."
Dirk Arnold, M.D., Ph.D.,
Director of Asklepios Tumorzentrum Hamburg and primary
investigator of the GOBLET trial commented, "I have been pleased to
observe the strength of the clinical response data for pelareorep
in multiple cohorts of the GOBLET gastrointestinal study,
especially in pancreatic and anal cancer. mFOLFIRINOX is currently
considered the best treatment option for many pancreatic cancer
patients. Therefore, the evaluation of pelareorep and mFOLFIRINOX,
with or without atezolizumab, presents an important opportunity to
identify a novel therapeutic approach that may broaden the
population of metastatic pancreatic cancer patients who could
benefit from pelareorep-based therapies."
"Oncolytics is in a favorable position as we prepare to
advance multiple pelareorep programs toward registration track
studies and continue to expand pelareorep's potential as a backbone
immunotherapy that can impact various tumor types. The
collaboration with GCAR on a registration-enabling study for the
combination of pelareorep, atezolizumab, gemcitabine, and
nab-paclitaxel in pancreatic cancer, meeting with the FDA to align
on next steps for our breast cancer program, expanded enrollment in
the GOBLET anal cancer cohort, and now the initiation of dosing in
the mFOLFIRINOX cohort of GOBLET, announced today, are all
important elements of our corporate plan," said Dr. Matt Coffey, President and Chief Executive
Officer of Oncolytics. "The ability to improve the lives of
cancer patients is something that motivates everyone at
Oncolytics, and beginning to treat pancreatic cancer
patients in the mFOLFIRINOX cohort of GOBLET is hopefully yet
another step towards that goal."
CONTINUED… Read this and more news for Avant Technologies
at: https://equity-insider.com/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
In other industry developments and happenings in the market
this week include:
Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage
biopharmaceutical company, recently announced favorable
efficacy and safety data from its Phase 1/2 trial of MB-106, a
CD20-targeted CAR T-cell therapy for Waldenstrom macroglobulinemia
(WM). The trial showed a 90% overall response rate (ORR), with one
patient in complete remission for 31 months.
"We are very encouraged by the safety and efficacy data
generated in WM, along with improvements in the quality of
responses over time, which demonstrates MB-106 CAR T-cell expansion
and persistence," said Dr. Brian
Till, M.D., Associate Professor and physician at
Fred Hutch and
University of Washington. Upon
hearing the results of the study data, the market responded quickly
and positively.
Legend Biotech Corporation (NASDAQ: LEGN), a global cell
therapy leader, announced first-time results from the Phase 2
CARTITUDE-2 Cohort D study in multiple myeloma patients. Presented
at ASCO 2024, findings showed deep and durable responses in
patients with less than a complete response after front-line
autologous stem cell transplant (ASCT) following a single infusion
of CARVYKTI® (ciltacabtagene autoleucel) with or without
lenalidomide maintenance. CARVYKTI® is the first B-cell maturation
antigen (BCMA)-targeted therapy approved for treating
relapsed/refractory multiple myeloma after the first relapse.
"Patients who achieve a less than complete response following
ASCT may experience less durable response with future treatments,"
said Melissa Alsina, M.D., Head
Myeloma BMT-CI Program, H. Lee Moffitt Cancer Center, and
Research Institute. "The outcomes from this study showed
encouraging efficacy results and indicated the potential benefit of
CARVYTKI in this patient population."
Johnson & Johnson (NYSE: JNJ) has submitted a
Biologics License Application (BLA) to the FDA for a
subcutaneous (SC) version of amivantamab combined with recombinant
human hyaluronidase. This application covers all current and
pending indications of intravenous (IV) RYBREVANT®
(amivantamab-vmjw) for certain non-small cell lung cancer (NSCLC)
patients.
Data from the Phase 3 PALOMA-3 study, presented at ASCO 2024,
showed that SC amivantamab had similar response rates to IV
administration in NSCLC patients with epidermal growth factor
receptor (EGFR) exon 19 deletion or L858R mutations. Additionally,
SC amivantamab offered significantly shorter administration time, a
five-fold reduction in infusion-related reactions, and improved
overall survival, progression-free survival, and duration of
response.
"This subcutaneous option, administered in approximately five
minutes, is a clinically important advancement that could transform
the treatment experience for patients, oncologists and nursing
staff," said Kiran Patel, M.D., Vice
President, Clinical Development, Solid Tumors, Johnson &
Johnson Innovative Medicine. "We look forward to working with
the FDA and global regulators in the review of these
applications."
Nurix Therapeutics, Inc. (NASDAQ: NRIX), a clinical-stage
biopharma company, recently presented updated clinical
data for NX-5948, an oral Bruton's tyrosine kinase (BTK)
degrader in a Phase 1a/b trial for relapsed/refractory B-cell
malignancies like chronic lymphocytic leukemia (CLL) and
non-Hodgkin lymphoma. The trial showed a 69.2% objective response
rate in heavily pretreated patients, including those with BTK
inhibitor resistance mutations, leading to a positive market
response.
"The current results from this study of advanced patients are
very impressive for this early stage of development and we are
optimistic that NX-5948 has the potential to be an exciting
breakthrough for patients with relapsed CLL, particularly in light
of the emerging patterns of resistance to the currently available
targeted therapies," said Dr. Kim
Linton, M.B.Ch.B, MRCP, Ph.D., FRCP, senior lecturer at the
University of Manchester, a
consultant at The Christie NHS Foundation Trust and an
investigator on the clinical trial. "As a clinical investigator, it
is highly gratifying to be able to offer patients who are
refractory to other therapies a once daily, oral drug that can
address a range of CLL disease states."
Source:
https://equity-insider.com/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604)
265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for Oncolytics Biotech Inc. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares of Oncolytics Biotech Inc., and may liquidate their
shares which could have a negative effect on the price of the
stock. This compensation constitutes a conflict of interest as to
our ability to remain objective in our communication regarding the
profiled company. Because of this conflict, individuals are
strongly encouraged to not use this publication as the basis for
any investment decision. The owner/operator of MIQ own shares of
Oncolytics Biotech Inc. which were purchased in the open market,
and reserve the right to buy and sell, and will buy and sell shares
of Oncolytics Biotech Inc. at any time without any further notice
commencing immediately and ongoing. We also expect further
compensation as an ongoing digital media effort to increase
visibility for the company, no further notice will be given, but
let this disclaimer serve as notice that all material, including
this article, which is disseminated by MIQ has been approved by
Oncolytics Biotech Inc.; this is a paid advertisement, we currently
own shares of Oncolytics Biotech Inc. and will buy and sell shares
of the company in the open market, or through private placements,
and/or other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between the any predictions and actual
results. Always consult a licensed investment professional before
making any investment decision. Be extremely careful, investing in
securities carries a high degree of risk; you may likely lose some
or all of the investment.
View original
content:https://www.prnewswire.co.uk/news-releases/biotech-advances-propel-oncology-market-to-564-5b-amid-youth-cancer-spike-302178538.html